Cargando…

Serum phosphorylated tau protein 181 and neurofilament light chain in cognitively impaired heart failure patients

BACKGROUND: Chronic heart failure (HF) is known to increase the risk of developing Alzheimer’s dementia significantly. Thus, detecting and preventing mild cognitive impairment, which is common in patients with HF, is of great importance. Serum biomarkers are increasingly used in neurological disorde...

Descripción completa

Detalles Bibliográficos
Autores principales:	Traub, Jan, Otto, Markus, Sell, Roxane, Göpfert, Dennis, Homola, György, Steinacker, Petra, Oeckl, Patrick, Morbach, Caroline, Frantz, Stefan, Pham, Mirko, Störk, Stefan, Stoll, Guido, Frey, Anna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9549648/ https://www.ncbi.nlm.nih.gov/pubmed/36217177 http://dx.doi.org/10.1186/s13195-022-01087-4

Ejemplares similares

Serum glial fibrillary acidic protein indicates memory impairment in patients with chronic heart failure
por: Traub, Jan, et al.
Publicado: (2022)

Profiles of cognitive impairment in chronic heart failure—A cluster analytic approach
por: Göpfert, Dennis, et al.
Publicado: (2023)

Internal carotid artery blood flow and pulsatility index in cognitively impaired people with chronic heart failure
por: Traub, Jan, et al.
Publicado: (2023)

Temporal changes in total and hippocampal brain volume and cognitive function in patients with chronic heart failure—the COGNITION.MATTERS-HF cohort study
por: Frey, Anna, et al.
Publicado: (2021)

Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease
por: Moscoso, Alexis, et al.
Publicado: (2021)

Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer’s disease pathology and clinical disease progression
por: Clark, Christopher, et al.
Publicado: (2021)

Plasma p-tau181, neurofilament light chain and association with cognition in Parkinson’s disease
por: Batzu, Lucia, et al.
Publicado: (2022)

Serum β-synuclein, neurofilament light chain and glial fibrillary acidic protein as prognostic biomarkers in moderate-to-severe acute ischemic stroke
por: Barba, Lorenzo, et al.
Publicado: (2023)

Plasma phosphorylated tau181 and neurodegeneration in Alzheimer’s disease
por: Hansson, Oskar, et al.
Publicado: (2020)

Associations of plasma phosphorylated tau181 and neurofilament light chain with brain amyloid burden and cognition in objectively defined subtle cognitive decline patients
por: Huang, Yanlu, et al.
Publicado: (2022)

Neurofilaments in blood and CSF for diagnosis and prediction of onset in Creutzfeldt-Jakob disease
por: Steinacker, Petra, et al.
Publicado: (2016)

Plasma phosphorylated tau181 predicts cognitive and functional decline
por: Tropea, Thomas F., et al.
Publicado: (2022)

Estimation of Tau and Phosphorylated Tau(181) in Serum of Alzheimer’s Disease and Mild Cognitive Impairment Patients
por: Shekhar, Shashank, et al.
Publicado: (2016)

Plasma β‐synuclein, GFAP, and neurofilaments in patients with malignant gliomas undergoing surgical and adjuvant therapy
por: Abu‐Rumeileh, Samir, et al.
Publicado: (2023)

Plasma phosphorylated-tau181 as a predictive biomarker for Alzheimer’s amyloid, tau and FDG PET status
por: Shen, Xue-Ning, et al.
Publicado: (2021)

Longitudinal plasma phosphorylated tau 181 tracks disease progression in Alzheimer’s disease
por: Chen, Shi-Dong, et al.
Publicado: (2021)

Time course of phosphorylated-tau181 in blood across the Alzheimer’s disease spectrum
por: Moscoso, Alexis, et al.
Publicado: (2020)

Phosphorylated Tau 181 Serum Levels Predict Alzheimer’s Disease in the Preclinical Stage
por: Qin, Wei, et al.
Publicado: (2022)

Chronic Neuroinflammation and Cognitive Decline in Patients with Cardiac Disease: Evidence, Relevance, and Therapeutic Implications
por: Traub, Jan, et al.
Publicado: (2023)

Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration
por: Thijssen, Elisabeth H., et al.
Publicado: (2020)

Erratum to: Time course of phosphorylated-tau181 in blood across the Alzheimer’s disease spectrum
Publicado: (2021)

Correlation between cognitive impairment and serum phosphorylated tau181 protein in patients with preeclampsia
por: Wang, Yuanyuan, et al.
Publicado: (2023)

Ultrasensitive assays for detection of plasma tau and phosphorylated tau 181 in Alzheimer’s disease: a systematic review and meta-analysis
por: Ding, Xulong, et al.
Publicado: (2021)

Neurofilament light and heterogeneity of disease progression in amyotrophic lateral sclerosis: development and validation of a prediction model to improve interventional trials
por: Witzel, Simon, et al.
Publicado: (2021)

Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer’s disease in adults with Down syndrome
por: Lleó, Alberto, et al.
Publicado: (2021)

Elevation of plasma phosphorylated tau181 during neurological illnesses affecting consciousness and kidney dysfunction
por: Thanapornsangsuth, Poosanu, et al.
Publicado: (2022)

Sustained Increase in Serum Glial Fibrillary Acidic Protein after First ST-Elevation Myocardial Infarction
por: Traub, Jan, et al.
Publicado: (2022)

Neurofilament heavy chain side arm phosphorylation regulates axonal transport of neurofilaments
por: Ackerley, Steven, et al.
Publicado: (2003)

Plasma Phosphorylated-tau181 Is a Predictor of Post-stroke Cognitive Impairment: A Longitudinal Study
por: Huang, Li-Kai, et al.
Publicado: (2022)

Plasma phosphorylated tau 181 predicts amyloid status and conversion to dementia stage dependent on renal function
por: Lehmann, Sylvain, et al.
Publicado: (2023)

Sex‐specific bimodal clustering of left ventricular ejection fraction in patients with acute heart failure
por: Henneges, Carsten, et al.
Publicado: (2021)

Association of Longitudinal Changes in Cerebrospinal Fluid Total Tau and Phosphorylated Tau 181 and Brain Atrophy With Disease Progression in Patients With Alzheimer Disease
por: Llibre-Guerra, Jorge J., et al.
Publicado: (2019)

Reference intervals for plasma amyloid-β, total tau, and phosphorylated tau181 in healthy elderly Chinese individuals without cognitive impairment
por: Chen, Jingshan, et al.
Publicado: (2023)

Plasma amyloid beta 40/42, phosphorylated tau 181, and neurofilament light are associated with cognitive impairment and neuropathological changes among World Trade Center responders: A prospective cohort study of exposures and cognitive aging at midlife
por: Kritikos, Minos, et al.
Publicado: (2023)

Objective subtle cognitive decline and plasma phosphorylated tau181: Early markers of Alzheimer's disease‐related declines
por: Thomas, Kelsey R., et al.
Publicado: (2021)

Plasma levels of phosphorylated tau 181 are associated with cerebral metabolic dysfunction in cognitively impaired and amyloid-positive individuals
por: Lussier, Firoza Z, et al.
Publicado: (2021)

Plasma α‐synuclein and phosphorylated tau 181 as a diagnostic biomarker panel for de novo Parkinson’s disease
por: Ren, Jingru, et al.
Publicado: (2022)

Neurofilament protein is phosphorylated in the squid giant axon
por: Pant, H. C., et al.
Publicado: (1978)

Clinical value of neurofilament and phospho-tau/tau ratio in the frontotemporal dementia spectrum
por: Meeter, Lieke H.H., et al.
Publicado: (2018)

Posttranscriptional regulation of neurofilament proteins and tau in health and disease
por: Yuan, Aidong, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_bhmo7jm1mdodhfmmgltgslu8fp